nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—lymph node—gallbladder cancer	0.00607	0.101	CbGeAlD
Thalidomide—FGFR2—epithelium—gallbladder cancer	0.00598	0.0997	CbGeAlD
Thalidomide—CRBN—pancreas—gallbladder cancer	0.00595	0.0991	CbGeAlD
Thalidomide—NFKB1—liver—gallbladder cancer	0.00452	0.0752	CbGeAlD
Thalidomide—CRBN—liver—gallbladder cancer	0.00378	0.063	CbGeAlD
Thalidomide—PTGS2—gall bladder—gallbladder cancer	0.00351	0.0585	CbGeAlD
Thalidomide—NFKB1—lymph node—gallbladder cancer	0.00346	0.0577	CbGeAlD
Thalidomide—FGFR2—liver—gallbladder cancer	0.00339	0.0565	CbGeAlD
Thalidomide—CRBN—lymph node—gallbladder cancer	0.0029	0.0483	CbGeAlD
Thalidomide—CYP1A1—epithelium—gallbladder cancer	0.00217	0.0361	CbGeAlD
Thalidomide—PTGS1—epithelium—gallbladder cancer	0.0019	0.0317	CbGeAlD
Thalidomide—CYP3A5—pancreas—gallbladder cancer	0.00189	0.0314	CbGeAlD
Thalidomide—PTGS2—epithelium—gallbladder cancer	0.00182	0.0303	CbGeAlD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—HRAS—gallbladder cancer	0.00176	0.00187	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—gallbladder cancer	0.00175	0.00186	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—gallbladder cancer	0.00175	0.00186	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—ERBB2—gallbladder cancer	0.00175	0.00186	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—ERBB2—gallbladder cancer	0.00174	0.00185	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—ERBB2—gallbladder cancer	0.00173	0.00185	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events—HRAS—gallbladder cancer	0.00173	0.00184	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—HRAS—gallbladder cancer	0.00172	0.00182	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.0017	0.00181	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—HRAS—gallbladder cancer	0.00169	0.0018	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—HRAS—gallbladder cancer	0.00167	0.00178	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—HRAS—gallbladder cancer	0.00167	0.00178	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—BCL2—gallbladder cancer	0.00165	0.00176	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KEAP1—gallbladder cancer	0.00165	0.00175	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—ERBB2—gallbladder cancer	0.00165	0.00175	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—BCL2—gallbladder cancer	0.00163	0.00174	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—KRAS—gallbladder cancer	0.00163	0.00174	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—NRAS—gallbladder cancer	0.00162	0.00173	CbGpPWpGaD
Thalidomide—PTGS2—pancreas—gallbladder cancer	0.00162	0.027	CbGeAlD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—gallbladder cancer	0.00161	0.00171	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—gallbladder cancer	0.0016	0.0017	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	0.0016	0.0017	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—TP53—gallbladder cancer	0.00158	0.00169	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—KRAS—gallbladder cancer	0.00158	0.00168	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—ERBB2—gallbladder cancer	0.00157	0.00168	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KEAP1—gallbladder cancer	0.00156	0.00166	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—NRAS—gallbladder cancer	0.00155	0.00165	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—NRAS—gallbladder cancer	0.00155	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—HRAS—gallbladder cancer	0.00155	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—HRAS—gallbladder cancer	0.00154	0.00164	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—NRAS—gallbladder cancer	0.00153	0.00163	CbGpPWpGaD
Thalidomide—CYP2C19—liver—gallbladder cancer	0.00152	0.0254	CbGeAlD
Thalidomide—TNF—Apoptosis—TP53—gallbladder cancer	0.00151	0.0016	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.00151	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—gallbladder cancer	0.00149	0.00159	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—NRAS—gallbladder cancer	0.00149	0.00158	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—EGFR—gallbladder cancer	0.00148	0.00157	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EGFR—gallbladder cancer	0.00147	0.00157	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—NRAS—gallbladder cancer	0.00146	0.00155	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—NRAS—gallbladder cancer	0.00145	0.00154	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—NRAS—gallbladder cancer	0.00144	0.00154	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.00144	0.00154	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—NRAS—gallbladder cancer	0.00144	0.00153	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—NRAS—gallbladder cancer	0.00143	0.00152	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—NRAS—gallbladder cancer	0.00142	0.00151	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—EGFR—gallbladder cancer	0.00141	0.0015	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—EGFR—gallbladder cancer	0.00141	0.0015	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—KRAS—gallbladder cancer	0.0014	0.00149	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	0.00139	0.00148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—EGFR—gallbladder cancer	0.00139	0.00148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—HRAS—gallbladder cancer	0.00139	0.00148	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.00138	0.00147	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—EGFR—gallbladder cancer	0.00137	0.00146	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—gallbladder cancer	0.00136	0.00145	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—EGFR—gallbladder cancer	0.00135	0.00144	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—NRAS—gallbladder cancer	0.00135	0.00144	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—NRAS—gallbladder cancer	0.00135	0.00144	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—NRAS—gallbladder cancer	0.00135	0.00144	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.00134	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB4—gallbladder cancer	0.00134	0.00143	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—HRAS—gallbladder cancer	0.00134	0.00143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—NRAS—gallbladder cancer	0.00134	0.00143	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—KRAS—gallbladder cancer	0.00134	0.00142	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—KRAS—gallbladder cancer	0.00134	0.00142	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—EGFR—gallbladder cancer	0.00133	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—NRAS—gallbladder cancer	0.00133	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—EGFR—gallbladder cancer	0.00132	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—NRAS—gallbladder cancer	0.00132	0.00141	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—NRAS—gallbladder cancer	0.00132	0.0014	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—EGFR—gallbladder cancer	0.00132	0.0014	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—KRAS—gallbladder cancer	0.00132	0.0014	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—EGFR—gallbladder cancer	0.00131	0.00139	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—EGFR—gallbladder cancer	0.0013	0.00138	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—gallbladder cancer	0.00129	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB4—gallbladder cancer	0.00129	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.00129	0.00137	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.00128	0.00136	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—KRAS—gallbladder cancer	0.00128	0.00136	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—ERBB2—gallbladder cancer	0.00128	0.00136	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB4—gallbladder cancer	0.00127	0.00136	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—KRAS—gallbladder cancer	0.00126	0.00134	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—NRAS—gallbladder cancer	0.00125	0.00133	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—KRAS—gallbladder cancer	0.00125	0.00133	CbGpPWpGaD
Thalidomide—CYP1A2—liver—gallbladder cancer	0.00124	0.0207	CbGeAlD
Thalidomide—FGFR2—Signaling by ERBB2—KRAS—gallbladder cancer	0.00124	0.00132	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	0.00124	0.00132	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—KRAS—gallbladder cancer	0.00124	0.00132	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—EGFR—gallbladder cancer	0.00123	0.00131	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—EGFR—gallbladder cancer	0.00123	0.00131	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—EGFR—gallbladder cancer	0.00123	0.00131	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—HRAS—gallbladder cancer	0.00123	0.00131	CbGpPWpGaD
Thalidomide—CYP1A1—liver—gallbladder cancer	0.00123	0.0204	CbGeAlD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	0.00123	0.00131	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB4—gallbladder cancer	0.00122	0.0013	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.00122	0.0013	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—EGFR—gallbladder cancer	0.00122	0.0013	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.00122	0.0013	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—NRAS—gallbladder cancer	0.00122	0.0013	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—ERBB2—gallbladder cancer	0.00121	0.00129	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—EGFR—gallbladder cancer	0.00121	0.00129	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—EGFR—gallbladder cancer	0.00121	0.00128	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—EGFR—gallbladder cancer	0.0012	0.00128	CbGpPWpGaD
Thalidomide—CYP3A5—liver—gallbladder cancer	0.0012	0.02	CbGeAlD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—NRAS—gallbladder cancer	0.0012	0.00127	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—HRAS—gallbladder cancer	0.00119	0.00126	CbGpPWpGaD
Thalidomide—CYP2C9—liver—gallbladder cancer	0.00118	0.0197	CbGeAlD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	0.00116	0.00124	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—KRAS—gallbladder cancer	0.00116	0.00124	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—KRAS—gallbladder cancer	0.00116	0.00124	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB3—gallbladder cancer	0.00116	0.00124	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.00115	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—KRAS—gallbladder cancer	0.00115	0.00123	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—gallbladder cancer	0.00115	0.00122	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—KRAS—gallbladder cancer	0.00114	0.00122	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—EGFR—gallbladder cancer	0.00114	0.00121	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—KRAS—gallbladder cancer	0.00114	0.00121	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—gallbladder cancer	0.00114	0.00121	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	0.00114	0.00121	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—KRAS—gallbladder cancer	0.00114	0.00121	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—NRAS—gallbladder cancer	0.00113	0.0012	CbGpPWpGaD
Thalidomide—CYP2E1—liver—gallbladder cancer	0.00112	0.0186	CbGeAlD
Thalidomide—FGFR2—Signaling by ERBB4—HRAS—gallbladder cancer	0.00112	0.00119	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—gallbladder cancer	0.00112	0.00119	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB3—gallbladder cancer	0.00112	0.00119	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB3—gallbladder cancer	0.0011	0.00117	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.00109	0.00116	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—EGFR—gallbladder cancer	0.00109	0.00116	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—KRAS—gallbladder cancer	0.00108	0.00115	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—HRAS—gallbladder cancer	0.00107	0.00114	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—HRAS—gallbladder cancer	0.00106	0.00113	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB3—gallbladder cancer	0.00106	0.00113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—HRAS—gallbladder cancer	0.00106	0.00112	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HRAS—gallbladder cancer	0.00105	0.00112	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—KRAS—gallbladder cancer	0.00105	0.00112	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—gallbladder cancer	0.00105	0.00112	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	0.00104	0.00111	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.00104	0.0011	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—gallbladder cancer	0.00103	0.0011	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	0.00103	0.0011	CbGpPWpGaD
Thalidomide—PTGS2—liver—gallbladder cancer	0.00103	0.0172	CbGeAlD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.00103	0.00109	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	0.00102	0.00108	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—gallbladder cancer	0.00102	0.00108	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	0.00099	0.00105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—gallbladder cancer	0.00099	0.00105	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—gallbladder cancer	0.00099	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NRAS—gallbladder cancer	0.000988	0.00105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—gallbladder cancer	0.000981	0.00104	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—KRAS—gallbladder cancer	0.000975	0.00104	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	0.000972	0.00103	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—NRAS—gallbladder cancer	0.000971	0.00103	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—gallbladder cancer	0.000968	0.00103	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—gallbladder cancer	0.000965	0.00103	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.000962	0.00102	CbGpPWpGaD
Thalidomide—CYP1A1—lymph node—gallbladder cancer	0.000941	0.0157	CbGeAlD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.000931	0.000991	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—gallbladder cancer	0.000924	0.000983	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—gallbladder cancer	0.000922	0.00098	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—gallbladder cancer	0.000916	0.000974	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—gallbladder cancer	0.000892	0.000949	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—gallbladder cancer	0.000885	0.000941	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.00088	0.000936	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	0.000877	0.000933	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—gallbladder cancer	0.000866	0.000922	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.000855	0.00091	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—KRAS—gallbladder cancer	0.00085	0.000905	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—gallbladder cancer	0.000847	0.000901	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—gallbladder cancer	0.00084	0.000893	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KRAS—gallbladder cancer	0.000836	0.000889	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.000831	0.000884	CbGpPWpGaD
Thalidomide—PTGS1—lymph node—gallbladder cancer	0.000827	0.0138	CbGeAlD
Thalidomide—NFKB1—Developmental Biology—ERBB2—gallbladder cancer	0.000824	0.000877	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.000817	0.00087	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KRAS—gallbladder cancer	0.000793	0.000844	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—gallbladder cancer	0.000792	0.000843	CbGpPWpGaD
Thalidomide—PTGS2—lymph node—gallbladder cancer	0.00079	0.0132	CbGeAlD
Thalidomide—NFKB1—Immune System—ERBB4—gallbladder cancer	0.000782	0.000832	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000782	0.000832	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—BCL2—gallbladder cancer	0.000749	0.000797	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB4—gallbladder cancer	0.000742	0.00079	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB2—gallbladder cancer	0.000728	0.000775	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	0.000723	0.000769	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—BCL2—gallbladder cancer	0.000711	0.000757	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—gallbladder cancer	0.000711	0.000756	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—gallbladder cancer	0.000711	0.000756	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB2—gallbladder cancer	0.000699	0.000744	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB2—gallbladder cancer	0.000691	0.000735	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB4—gallbladder cancer	0.000685	0.000729	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB3—gallbladder cancer	0.000676	0.00072	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—gallbladder cancer	0.000674	0.000717	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB2—gallbladder cancer	0.000663	0.000706	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB3—gallbladder cancer	0.000642	0.000683	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ERBB2—gallbladder cancer	0.000628	0.000668	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—gallbladder cancer	0.000627	0.000667	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB3—gallbladder cancer	0.000593	0.00063	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.000576	0.000613	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—gallbladder cancer	0.000571	0.000608	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—gallbladder cancer	0.000554	0.000589	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.000544	0.000579	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—gallbladder cancer	0.00054	0.000574	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—gallbladder cancer	0.000532	0.000566	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—gallbladder cancer	0.000526	0.000559	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB4—gallbladder cancer	0.000506	0.000538	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—gallbladder cancer	0.000505	0.000537	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—gallbladder cancer	0.000505	0.000537	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—gallbladder cancer	0.000485	0.000516	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000484	0.000514	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB4—gallbladder cancer	0.00048	0.000511	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—gallbladder cancer	0.000479	0.000509	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—gallbladder cancer	0.000478	0.000508	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—gallbladder cancer	0.000477	0.000507	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—gallbladder cancer	0.00046	0.000489	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—gallbladder cancer	0.000459	0.000488	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—gallbladder cancer	0.000458	0.000487	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—gallbladder cancer	0.000452	0.000481	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB3—gallbladder cancer	0.000437	0.000465	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2—gallbladder cancer	0.000437	0.000464	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—gallbladder cancer	0.000435	0.000463	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—gallbladder cancer	0.000434	0.000462	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—gallbladder cancer	0.000424	0.000451	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB3—gallbladder cancer	0.000415	0.000441	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2—gallbladder cancer	0.000414	0.000441	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—gallbladder cancer	0.000411	0.000438	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—gallbladder cancer	0.000405	0.000431	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—gallbladder cancer	0.000402	0.000428	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—gallbladder cancer	0.000389	0.000414	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—gallbladder cancer	0.000385	0.000409	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—gallbladder cancer	0.000372	0.000395	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—gallbladder cancer	0.000369	0.000393	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—gallbladder cancer	0.00035	0.000372	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB4—gallbladder cancer	0.00034	0.000362	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—gallbladder cancer	0.000323	0.000343	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—gallbladder cancer	0.000306	0.000326	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB3—gallbladder cancer	0.000294	0.000313	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—gallbladder cancer	0.000294	0.000313	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—gallbladder cancer	0.000283	0.000301	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—gallbladder cancer	0.000279	0.000297	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—gallbladder cancer	0.000278	0.000295	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—gallbladder cancer	0.000274	0.000292	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—gallbladder cancer	0.000263	0.00028	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—gallbladder cancer	0.00026	0.000277	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—gallbladder cancer	0.000258	0.000274	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—gallbladder cancer	0.000243	0.000259	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—gallbladder cancer	0.000236	0.000251	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—gallbladder cancer	0.000224	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—gallbladder cancer	0.000209	0.000222	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—gallbladder cancer	0.000207	0.00022	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—gallbladder cancer	0.000198	0.000211	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—gallbladder cancer	0.00019	0.000202	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—gallbladder cancer	0.000184	0.000196	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—gallbladder cancer	0.00018	0.000192	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—gallbladder cancer	0.00018	0.000191	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—gallbladder cancer	0.00017	0.000181	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—gallbladder cancer	0.00016	0.00017	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—gallbladder cancer	0.000153	0.000162	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—gallbladder cancer	0.000151	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—gallbladder cancer	0.000145	0.000154	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—gallbladder cancer	0.00014	0.000149	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—gallbladder cancer	0.000128	0.000136	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—gallbladder cancer	0.000121	0.000129	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—gallbladder cancer	0.000103	0.000109	CbGpPWpGaD
